title: Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
abstract: OBJECTIVE
  The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented.
  
  
  METHODS
  Patients with measurable or evaluable advanced gastric cancer received IF weekly for 6/7 weeks or CF q4 weeks. QL was assessed using the EORTC QLQ-C30 at baseline, subsequently every 8 weeks until progression and thereafter every 3 months until death. The QL data were analysed using several statistical methods including summary measures and pattern-mixture modelling.
  
  
  RESULTS
  A total of 333 patients were randomised and treated (IF 170, CF 163). The time-to-progression for IF and CF was 5.0 and 4.2 months (P = 0.088), respectively. The overall compliance rates for QL questionnaire completion were 60 and 56% in the IF and CF arms, respectively. Significant treatment differences were observed for the physical functioning scale (P = 0.024), nausea\vomiting (P = 0.001) and EQ-5D thermometer (P = 0.020) in favour of the IF treatment arm.
  
  
  CONCLUSIONS
  There was a trend in favour of IF over CF in time-to-progression. The IF group also demonstrated a better safety profile than CF and a better QL on a number of multi-item scales, suggesting that IF offers an alternative first-line platinum-free treatment option for advanced gastric cancer.
authors: Omega Research, Santry, Dublin 9, Ireland. currandes@omega-research.eu.com
authors: Desmond
authors: D
authors: Curran
authors: Carmelo
authors: C
authors: Pozzo
authors: Jerzy
authors: J
authors: Zaluski
authors: Magdalena
authors: M
authors: Dank
authors: Carlo
authors: C
authors: Barone
authors: Vahur
authors: V
authors: Valvere
authors: Suayib
authors: S
authors: Yalcin
authors: Christian
authors: C
authors: Peschel
authors: Miklós
authors: M
authors: Wenczl
authors: Erdem
authors: E
authors: Goker
authors: Roland
authors: R
authors: Bugat
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000523:psychology*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage; D004943:Esophagogastric Junction / Q000473:pathology*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010166:Palliative Care / Q000379:methods*; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology*; D055815:Young Adult
chemical_list: D000077146:Irinotecan; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin